Wednesday, May 12, 2010
Recent Announcements Suggest Cellceutix Is Well Positioned With Autism Compound
"These announcements indicate that Cellceutix is in a prime position in the development of treatments for autism spectrum disorder," said Leo Ehrlich, the Chief Financial Officer of Cellceutix. "We are developing a novel compound for a disorder which has few treatment options. In an area that people were once skeptical about pharmaceutical advancements being possible, it is encouraging to see other companies showing significant interest."
Read more about this on the MarketWatch.
Cellceutix acquired the rights to KM-391, its compound for the treatment of autism spectrum disorder, last year and has been diligently developing the compound since. Cellceutix has already completed an animal study that shows very encouraging results. Details of the data from the study are available at the Cellceutix website at www.cellceutix.com.
Monday, April 19, 2010
Picky Eating is Common in Autistic Children, May Be at Nutritional Risk
Two new studies out this year have focused on the nutritional adequacy of diet in children with autism, particularly those who are selective about what they eat. Many children are picky eaters as they go through the more independent stages of toddlerhood and school-age years, but the trait is more common in children diagnosed with autistic spectrum disorders (ASD).
Autistic children have limitations or difficulties in several key areas of development, including language, communication, social interaction, and rigid or repetitive behavior. “Selective eating”, the clinical term for a picky eater, can be a component of the desire to have a more structured environment. While most children outgrow their tendency to be picky about what they eat, children with ASD often carry the trait into adulthood.
The rest of this article can be found here.